SFU Library Licensed Material

Access to the content in this collection is restricted to current SFU faculty, students, and staff.

This collection contains various types of content licensed by the SFU Library on behalf of the University. 

Copyright and Terms of use

This work is protected by copyright in Canada unless its copyright has expired. The user is responsible for doing their own assessment. 

You may use this work as permitted by applicable licenses, fair dealing and other exceptions under copyright legislation in your jurisdiction. For guidance on seeking further permissions, contact the source/owner of the material.

Search within Collection

Displaying 331 - 345 of 710

Overcoming Barriers to Leadership for Young Women

sfulibr_1678-Thumbnail Image.png
Date: 2013-12-18
Name(s): Hawkins, Naoko

Packaging of Category A and Category B infectious substances (Class 6.2) and clinical, (bio) medical or regulated medical waste

sfulibr_1223-Thumbnail Image.png
Date: 2016-04-27

Patent Protection Strategies,Datamonitor report

BI00027-006-Thumbnail Image.png
Date: 2007-08-01
Name(s): Norman, Peter
Description: Understanding how to effectively reassess, develop and exploit patent protection strategies is essential in facilitating enhanced market exclusivity and revenue returns over the lifecycles of new drugs.

Patient Recruitment and Retention in Clinical Trials,Datamonitor report

BI00025-002-Thumbnail Image.png
Date: 2007-05-31
Name(s): Sahoo, Alison
Description: Clinical trials are increasingly becoming a bottleneck as recruiting patients in established markets becomes increasingly difficult. To address this CROs and other clinical specialists have developed a number of strategies with varying success.

Pharmaceutical Branding Strategies,Datamonitor report

BI00027-047-Thumbnail Image.png
Date: 2006-01-25
Name(s): Seget, Steven
Description: Branding is a central issue in the pharma industry. But while the FMCG industry has highly sophisticated branding models, pharma is much less developed and product managers need to put brand equity at the heart of product development and marketing.

Pharmaceutical Licensing Strategies,Datamonitor report

BI00027-050-Thumbnail Image.png
Date: 2006-06-26
Name(s): Seget, Steven
Description: With falling R&D productivity, continued healthcare cost containment and the threat of generic competition, only companies who combine internal efforts with effective licensing strategies will remain competitive over the next five to ten years.

Pharmaceutical Project and Portfolio Management,Datamonitor report

BI00027-045-Thumbnail Image.png
Date: 2005-06-23
Name(s): Seget, Steven
Description: Pharma companies operate in multi-project, multi-product environments. The challenge facing executives is to decide which projects - each may have a strong value proposition and be championed by different business units - should receive investment.

Pharmaceutical Sales Force Effectiveness Strategies,Datamonitor report

BI00027-022-Thumbnail Image.png
Date: 2009-08-01
Name(s): Jakovcic, Ksenija
Description: Sales and marketing is under real scrutiny as pharma companies seek to become more efficient across their business. The gap between sales force growth and the decline in prescribing has made sales force effectiveness the key focus for sales managers.

Pharmaceutical Strategic Alliances,Datamonitor report

BI00027-001-Thumbnail Image.png
Date: 2006-09-27
Name(s): Seget, Steven
Description: Pharma and biotech companies have had to move fast to develop the licensing and alliance management capabilities required to compete in this new paradigm of collaboration.

Pharmacoeconomic Analysis in R&D Decision Making,Datamonitor report

BI00040-004-Thumbnail Image.png
Date: 2011-10-31
Name(s): Barton, Cheryl L., Sleigh, Sara
Description: The increasing use of HTAs in reimbursement decisions is leading to some products not gaining reimbursement. Pharmacoeconomic studies carried out by industry can help R&D go/no-go decisions when determining the likelihood of gaining reimbursement.

Point of Care Testing,Datamonitor report

BI00021-007-Thumbnail Image.png
Date: 2010-01-22
Description: Diagnostics are undergoing a revolution, with IVD tests moving out of the centralized hospital laboratory to the point of care. POC tests are more expensive than lab-based tests, but promise to reduce the total cost of treatment and improve outcomes.

Post-Recessionary Strategies for Food and Drinks Companies,Datamonitor report

BI00014-021-Thumbnail Image.png
Date: 2009-10-24
Name(s): Dodds, Andrew
Description: This report looks at how the recession has impacted consumer demand and buying behavior, and how the grocery industry is evolving strategies to suit the challenging business environment in Europe and the US.

Power Infrastructure in Europe,Datamonitor report

BI00036-024-Thumbnail Image.png
Date: 2012-04-24
Name(s): Price, Anthony
Description: The power system of today is on the threshold of significant change. A vision for a new power system comprising advanced generation, transmission, and distribution technologies is being debated at national and international levels.

Preclinical Development of Monoclonal Antibodies and Related Biologicals,Datamonitor report

BI00020-028-Thumbnail Image.png
Date: 2010-03-13
Name(s): Shirvill, James
Description: Monoclonal antibodies are a very high growth segment, with annual sales expected to top $50bn in the next four years. 23 full-size monoclonal antibodies and 3 monoclonal antibody fragments have been launched, with many reaching blockbuster status.

Preclinical Models,Datamonitor report

BI00020-027-Thumbnail Image.png
Date: 2010-02-10
Name(s): Atkinson, Tim
Description: Problems with traditional animal models such as cost, ethics, and suitability have prompted researchers to develop new models and systems. Increasingly they are turning to new vertebrate, nonvertebrate, computer-based and imaging models.